MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with Chemical Subclasses of Psilocybin Analogues
- Wednesday, June 23, 2021, 7:13
- PR Newswire
- Add a comment
VANCOUVER, BC, June 23, 2021 /PRNewswire/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND”) a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce it has expanded its intellectual property…
About the Author
admin has written 20655 stories on this site.